In summary, our results exclude variation in blood-derived DNA methylation in SMN2 as an epigenetic biomarker of clinical SMA outcomes but highlight DNA methylation as a possible modifier of SMN expression. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.